Chew-Harris Janice S C, Florkowski Christopher M, George Peter M, Endre Zoltan H
Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand; Departments of Pathology and Medicine, University of Otago, Christchurch, New Zealand.
Asia Pac J Clin Oncol. 2015 Jun;11(2):142-51. doi: 10.1111/ajco.12312. Epub 2014 Dec 3.
In cancer patients receiving chemotherapy treatment, accurate assessment of kidney function is required. The aim of our study was to investigate whether the inclusion of cystatin C together with creatinine in prediction equations would improve the prediction of glomerular filtration rate (GFR).
Plasma creatinine and cystatin C were analyzed in 155 patients (cancer, n = 80, kidney donors, n = 75) undergoing (99m) Technetium diethylenepentaacetic (Tc-DTPA) GFR clearance. Equations by the CKD-EPI (chronic kidney disease epidemiology) group (creatinine-, creatinine + cystatin C-, cystatin C-based, respectively) and Cockcroft-Gault were compared with Tc-DTPA GFR by difference plots, receiver operator characteristics curve analysis, root mean square error, chi-squared analysis and percentage concordance according to carboplatin dosage. Comparisons between two creatinine methodologies (enzymatic vs Jaffe) were also performed.
In the overall group, the combination creatinine and cystatin C equation had 69% of results within 20% of GFR (P20), a sensitivity of 86.3% and a specificity of 73.1% to detect reduced GFR at <90 mL/min/1.73 m(2), and a concordance of 78%. In contrast, the traditional Cockcroft-Gault equation had a P20 of 38.0%, with a large underestimation to predict GFR, thereby accounting for approximately 45% of dosing discordance. No obvious differences were obtained when comparing the performance of equations using the two creatinine methodologies.
The inclusion of cystatin C in the CKD-EPI equations improved the prediction of kidney function in the overall population, although probably not sufficiently for it to be favored over radioisotopic GFR for guiding chemotherapy. More research is warranted to further improve estimated GFR equations for these purposes.
对于接受化疗的癌症患者,需要准确评估其肾功能。我们研究的目的是调查在预测方程中纳入胱抑素C和肌酐是否能改善对肾小球滤过率(GFR)的预测。
对155例患者(癌症患者80例,肾脏供体75例)进行了锝-二乙三胺五乙酸(Tc-DTPA)GFR清除率检测,并分析其血浆肌酐和胱抑素C水平。通过差异图、受试者操作特征曲线分析、均方根误差、卡方分析以及根据卡铂剂量计算的一致性百分比,将慢性肾脏病流行病学协作组(CKD-EPI)的方程(分别基于肌酐、肌酐+胱抑素C、胱抑素C)和Cockcroft-Gault方程与Tc-DTPA GFR进行比较。还对两种肌酐检测方法(酶法与Jaffe法)进行了比较。
在总体人群中,肌酐和胱抑素C联合方程得出的结果有69%在GFR的20%以内(P20),检测GFR<90 mL/min/1.73 m²时降低的敏感性为86.3%,特异性为73.1%,一致性为78%。相比之下,传统的Cockcroft-Gault方程的P20为38.0%,对GFR的预测有较大程度的低估,约占剂量不一致情况的45%。比较使用两种肌酐检测方法的方程性能时,未发现明显差异。
在CKD-EPI方程中纳入胱抑素C改善了总体人群肾功能的预测,尽管可能还不足以使其在指导化疗方面优于放射性同位素GFR。有必要进行更多研究以进一步改进用于这些目的的估计GFR方程。